Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoraco-mediastinal Radiotherapy With Maintenance Atezolizumab in Extensive Small Cell Lung Cancer
NCT06771518Phase 2Recruiting
- Sponsor
- IRCCS Regina Elena National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in small cell lung cancer (SCLC), sponsored by IRCCS Regina Elena National Cancer Institute. Primary endpoint: Efficacy of the association between radiotherapy and immunotherapy at 60 months. Started Dec 2021; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06771518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771518.